Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
May 02 2023 - 7:01AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced it
will report financial results for the first quarter 2023 on Monday,
May 8, 2023, before the opening of the U.S. financial markets.
Management will conduct a conference call at 8:00 AM ET on the
same day to discuss Aclaris’ financial results and to provide a
corporate update, including a summary of final results from the
Phase 2a trial of zunsemetinib (ATI-450) in subjects with moderate
to severe hidradenitis suppurativa. The conference call will be
webcast live over the internet and can be accessed by logging into
the “Investors” page of the Aclaris Therapeutics website,
www.aclaristx.com, prior to the event. The webcast will be archived
for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
Robert A. Doody Jr.Vice President, Investor
Relations484-639-7235rdoody@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024